Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis
Authors:
Open Access
- 23 June 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1598972
Abstract
Introduction: Upadacitinib, one of the Janus kinase (JAK) inhibitors, has gained global approval for treating various inflammatory and autoimmune diseases. However, despite the FDA’s black box warning on all JAK inhibitors, further research is necessary to verify the potential risks associated specifically with upadacitinib. Therefore, this study conducted a comprehensive systematic review and meta-analysis to assess the safety profile of upadacitinib and explore potential dose-related differences.Methods: Relevant English publications were identified through a comprehensive search of eligible databases conducted in March 2024 and subsequently updated in May 2025. The inclusion criteria focused on randomized controlled trials that included safety data on upadacitinib.Results: A total of 9,547 patients were involved in this meta-analysis. Upadacitinib treatment was associated with an increased risk of hepatic disorder, neutropenia, acne, herpes zoster, and increased creatine phosphokinase levels. Notably, the risks of hepatic disorder, neutropenia, and acne also exhibited a dose-dependent relationship. However, there was no significant association between upadacitinib treatment and an elevated risk of renal dysfunction, non-melanoma skin cancer (NMSC), major adverse cardiovascular event (MACE), or venous thromboembolic event (VTE).Conclusion: This study reveals that upadacitinib generally has a favorable safety profile, with increased risks of hepatic disorder, neutropenia, acne, especially at higher doses. There was no significant association with renal dysfunction, NMSC, MACE, or VTE. These findings may serve as an evidence base for potential future modifications or removal of the FDA’s black box warning for upadacitinib.Keywords
This publication has 39 references indexed in Scilit:
- Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statementAnnals of the Rheumatic Diseases, 2025
- Upadacitinib in Adolescents With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2024
- Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled TrialArthritis & Rheumatology, 2024
- Symptomatic creatine phosphokinase elevation in a Crohn's disease patient caused by upadacitinibClinical Case Reports, 2024
- Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesJournal of Allergy and Clinical Immunology, 2022
- Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trialsJournal of the American Academy of Dermatology, 2022
- JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor SafetyAmerican Journal of Clinical Dermatology, 2022
- Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialJournal of Allergy and Clinical Immunology, 2020
- Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled TrialArthritis & Rheumatology, 2019
- Characterization of the Effect of Renal Impairment on Upadacitinib PharmacokineticsThe Journal of Clinical Pharmacology, 2019